Financière de Tubize SA (TUB.BR)
EUR 132.8
(5.23%)
EUR 132.8
(5.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 184.57 Thousand EUR | 3.44% |
| 2022 | - EUR | -77.04% |
| 2021 | - EUR | 45.62% |
| 2020 | 997 Thousand EUR | 23643.22% |
| 2019 | -1.09 Million EUR | -99.62% |
| 2018 | -118 Thousand EUR | 6.2% |
| 2017 | -151 Thousand EUR | 46.65% |
| 2016 | -5.82 Million EUR | -14.03% |
| 2015 | 214.11 Million EUR | 207.95% |
| 2014 | 69.52 Million EUR | -5.6% |
| 2013 | 73.65 Million EUR | 17720.57% |
| 2012 | -13.35 Million EUR | -12.97% |
| 2011 | -14.68 Million EUR | -101.0% |
| 2010 | -15.92 Million EUR | 9457.36% |
| 2009 | -6.31 Million EUR | -177.41% |
| 2008 | 509 Thousand EUR | 389.42% |
| 2007 | -16.9 Million EUR | -99.93% |
| 2006 | 156.63 Million EUR | -48.4% |
| 2005 | 303.55 Million EUR | 129.71% |
| 2004 | 132.14 Million EUR | 2.54% |
| 2003 | 128.87 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -878.54 Thousand EUR | 0.0% |
| 2023 Q4 | -900.66 Thousand EUR | 0.0% |
| 2023 Q2 | -993.32 Thousand EUR | 0.0% |
| 2023 FY | - EUR | -102.17% |
| 2022 FY | - EUR | -77.04% |
| 2022 Q2 | -781 Thousand EUR | 0.0% |
| 2022 Q4 | -1.11 Million EUR | 0.0% |
| 2021 Q2 | -508 Thousand EUR | 0.0% |
| 2021 FY | - EUR | 45.62% |
| 2021 Q4 | -389 Thousand EUR | 0.0% |
| 2020 Q4 | -1.64 Million EUR | 0.0% |
| 2020 FY | - EUR | 23643.22% |
| 2020 Q2 | -481 Thousand EUR | 0.0% |
| 2019 FY | - EUR | -99.62% |
| 2019 Q2 | 147.75 Million EUR | 0.0% |
| 2019 Q4 | 137.06 Million EUR | 0.0% |
| 2018 FY | - EUR | 6.2% |
| 2018 Q1 | 71.88 Million EUR | -52.24% |
| 2018 Q4 | 87.94 Million EUR | 0.0% |
| 2018 Q2 | 198.03 Million EUR | 175.51% |
| 2017 Q2 | 155.99 Million EUR | 130.46% |
| 2017 FY | - EUR | 46.65% |
| 2017 Q4 | 150.5 Million EUR | 0.0% |
| 2017 Q1 | 67.69 Million EUR | -10.76% |
| 2016 FY | - EUR | -14.03% |
| 2016 Q4 | 75.85 Million EUR | 0.0% |
| 2016 Q2 | 108.46 Million EUR | 133.64% |
| 2016 Q1 | 46.42 Million EUR | -62.37% |
| 2015 FY | - EUR | 207.95% |
| 2015 Q3 | 54.08 Million EUR | -41.74% |
| 2015 Q4 | 123.36 Million EUR | 128.1% |
| 2015 Q2 | 92.83 Million EUR | 71.64% |
| 2015 Q1 | 54.08 Million EUR | 174.76% |
| 2014 Q4 | 19.68 Million EUR | 13.25% |
| 2014 FY | - EUR | -5.6% |
| 2014 Q3 | 17.38 Million EUR | -58.44% |
| 2014 Q1 | 17.38 Million EUR | -44.73% |
| 2014 Q2 | 41.82 Million EUR | 140.63% |
| 2013 Q2 | 15.29 Million EUR | -16.93% |
| 2013 Q1 | 18.41 Million EUR | 0.0% |
| 2013 Q4 | 31.45 Million EUR | 70.8% |
| 2013 Q3 | 18.41 Million EUR | 20.38% |
| 2013 FY | - EUR | 17720.57% |
| 2012 Q1 | 23.05 Million EUR | 0.0% |
| 2012 FY | - EUR | -12.97% |
| 2012 Q3 | 23.05 Million EUR | 0.0% |
| 2012 Q4 | 18.41 Million EUR | -20.13% |
| 2012 Q2 | 23.05 Million EUR | 0.0% |
| 2011 Q3 | 17.55 Million EUR | 0.0% |
| 2011 FY | - EUR | -101.0% |
| 2011 Q4 | 23.05 Million EUR | 31.36% |
| 2011 Q2 | 17.55 Million EUR | 0.0% |
| 2011 Q1 | 17.55 Million EUR | 0.0% |
| 2010 Q4 | 17.55 Million EUR | 90.42% |
| 2010 Q1 | 9.21 Million EUR | 0.0% |
| 2010 FY | - EUR | 9457.36% |
| 2010 Q3 | 9.21 Million EUR | 0.0% |
| 2010 Q2 | 9.21 Million EUR | 0.0% |
| 2009 Q4 | 9.21 Million EUR | -77.43% |
| 2009 Q1 | 40.84 Million EUR | 0.0% |
| 2009 Q2 | 40.84 Million EUR | 0.0% |
| 2009 FY | - EUR | -177.41% |
| 2009 Q3 | 40.84 Million EUR | 0.0% |
| 2008 Q1 | -266 Thousand EUR | 0.0% |
| 2008 Q3 | -266 Thousand EUR | 0.0% |
| 2008 Q2 | -266 Thousand EUR | 0.0% |
| 2008 Q4 | 40.84 Million EUR | 15454.23% |
| 2008 FY | - EUR | 389.42% |
| 2007 Q2 | 10.21 Million EUR | 0.0% |
| 2007 Q4 | -266 Thousand EUR | -102.6% |
| 2007 Q1 | 10.21 Million EUR | 0.0% |
| 2007 Q3 | 10.21 Million EUR | 0.0% |
| 2007 FY | - EUR | -99.93% |
| 2006 Q1 | 121.2 Million EUR | 0.0% |
| 2006 Q2 | 121.2 Million EUR | 0.0% |
| 2006 Q3 | 121.2 Million EUR | 0.0% |
| 2006 Q4 | 10.21 Million EUR | -91.57% |
| 2006 FY | - EUR | -48.4% |
| 2005 FY | - EUR | 129.71% |
| 2005 Q4 | 121.2 Million EUR | 59.72% |
| 2005 Q3 | 75.88 Million EUR | 0.0% |
| 2005 Q2 | 75.88 Million EUR | 0.0% |
| 2005 Q1 | 75.88 Million EUR | 0.0% |
| 2004 Q4 | 75.88 Million EUR | 129.71% |
| 2004 Q2 | 33.03 Million EUR | 0.0% |
| 2004 Q3 | 33.03 Million EUR | 0.0% |
| 2004 Q1 | 33.03 Million EUR | 0.0% |
| 2004 FY | - EUR | 2.54% |
| 2003 Q3 | 32.21 Million EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2003 Q2 | 32.21 Million EUR | 0.0% |
| 2003 Q1 | 32.21 Million EUR | 0.0% |
| 2003 Q4 | 33.03 Million EUR | 2.54% |
| 2002 Q4 | 32.21 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | 101.137% |
| European Medical Solutions | 59 Thousand EUR | -212.832% |
| FERMENTALG | -10.51 Million EUR | 101.756% |
| argenx SE | -199.5 Million EUR | 100.093% |
| BioSenic S.A. | -6.79 Million EUR | 102.716% |
| Celyad Oncology SA | -7.76 Million EUR | 102.378% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 101.232% |
| Onward Medical N.V. | -35.23 Million EUR | 100.524% |
| Oxurion NV | -16.72 Million EUR | 101.103% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 100.805% |
| UCB SA | 1.26 Billion EUR | 99.985% |